Immunomedics

Immunomedics
Traded as NASDAQ: IMMU
Russell 2000 Component
Website https://immunomedics.com

Immunomedics is a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer.

Immunomedics was founded in July 1982 by David M. Goldenberg, who has served on the board of directors since then. Michael Pehl is the current CEO since December 2017.[1]

Pipeline

  • Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.
  • Sacituzumab govitecan (IMMU-132) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors.
  • Labetuzumab govitecan (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.
  • Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.
  • Milatuzumab is an anti-CD74 monoclonal antibody for autoimmune diseases.
  • IMMU-114 is an anti-HLA-DR for hematological cancers.[2]

References

  1. ↑ "immu_CurrentFolio_10K". Sec.gov. Retrieved 2017-05-22.
  2. ↑ "Corporate overview" (PDF). www.immunomedics.com. February 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.